Quisinostat dihydrochloride
Based on 18 publication(s) in Google Scholar
Quisinostat dihydrochloride (JNJ-26481585 dihydrochloride) is an orally active, potent pan-HDAC inhibitor with IC50s of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM, and 0.37 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11, respectively. Quisinostat dihydrochloride has a broad spectrum antitumoral activity. Quisinostat dihydrochloride can induce autophagy in neuroblastoma cells.
For research use only. We do not sell to patients.
- Purity: 99.05%
- CAS No.: 875320-31-3
- Formula: C21H28Cl2N6O2
- Molecular Weight:467.39
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Orally Active Compound Library
HY-L061
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Osteogenesis Compound Library
HY-L131
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
MCE Bioactive Compound Library
HY-L001V
-
Anti-Brain Cancer Compound Library
HY-L188
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Quisinostat dihydrochloride
More- Cancer Cell. 2024 Oct 14;42(10):1729-1746.e8. [Abstract]
- Nat Commun. 2024 Jul 2;15(1):5570. [Abstract]
- Nat Commun. 2020 Apr 14;11(1):1792. [Abstract]
- Exp Hematol Oncol. 2019 Nov 15:8:30. [Abstract]
- Theranostics. 2019 Jan 30;9(4):1096-1114. [Abstract]
- Adv Sci (Weinh). 2026 Jan 22:e17877. [Abstract]
- NPJ Precis Oncol. 2023 Jul 21;7(1):70. [Abstract]
- EMBO J. 2024 Nov;43(21):4954-4983. [Abstract]
- Blood Adv. 2024 Sep 24;8(18):4936-4947. [Abstract]
- Cancer Cell Int. 2025 Oct 8;25(1):340. [Abstract]
- Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0181924. [Abstract]
- Toxicol Appl Pharmacol. 2021 Jan 1:410:115363. [Abstract]
- Int J Parasitol Drugs Drug Resist. 2026 May 17;31:100649.
- Patent. US20250161243A1.
- bioRxiv. 2025 January 15.
- bioRxiv. 2024 July 04.
- Albert-ludwigs-university Of Freiburg. 2019 Dec.
- Patent. US20180263995A1.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
IHC
-
In Vivo Efficacy Study
-
WB
-
IF
Biological Activity
|
HDAC1 0.11 nM (IC50) |
HDAC2 0.33 nM (IC50) |
HDAC3 4.86 nM (IC50) |
HDAC4 0.64 nM (IC50) |
HDAC5 3.69 nM (IC50) |
HDAC6 76.8 nM (IC50) |
HDAC7 119 nM (IC50) |
HDAC8 4.26 nM (IC50) |
HDAC9 32.1 nM (IC50) |
HDAC10 0.46 nM (IC50) |
HDAC11 0.37 nM (IC50) |
JNJ-26481585 inhibits HDAC isozymes in vitro[1].
JNJ-26481585 (30-1000 nM; 24 hours) is a potent pan-HDAC inhibitor in tumor cells[1].
JNJ-26481585 has broad spectrum antiproliferative activity against solid and hematologic cancer cell lines and induces apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human A2780 ovarian carcinoma cells
-
Concentration:30 nM, 100 nM, 300 nM, 1000 nM
-
Incubation Time:24 hours
-
Result:Induced H3 and H4 acetylation at concentrations as low as 30 to 100 nM.
JNJ-26481585 induces continuous H3 acetylation in tumor tissue in vivo[1].
JNJ-26481585 (10 mg/kg; once daily; i.p.; for 14 days) strongly inhibits the growth of large pre-established HCT116 colon xenografts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NMRI nude mice, with HCT116 colon carcinoma cells xenografts[1]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection, once daily, for 14 days
-
Result:Strongly inhibited the growth of large pre-established HCT116 colon xenografts.
Chemical Information
-
CAS No. 875320-31-3
-
Appearance Solid
-
Molecular Weight 467.39
-
Formula C21H28Cl2N6O2
-
Color White to yellow
-
SMILES
[H]Cl.O=C(C1=CN=C(N2CCC(CNCC3=CN(C)C4=C3C=CC=C4)CC2)N=C1)NO.[H]Cl
-
Synonyms
JNJ-26481585 dihydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. [Abstract]2024 Oct 14;42(10):1729-1746.e8. PMID: 39303724 -
Nat Commun
2024 Jul 2;15(1):5570. PMID: 38956053 -
Nat Commun
Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. [Abstract]2020 Apr 14;11(1):1792. PMID: 32286289
Quisinostat dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2020 Apr 14;11(1):1792. [Abstract]
Quisinostat (25–50 nM; 7 d) blocked proliferation without inducing substantial death of HCC1569 cells.
Quisinostat dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2020 Apr 14;11(1):1792. [Abstract]
Quisinostat (4 mg/kg; i.p.; 21 d) caused reduced fractions of proliferating Ki67+ cells and no increase in apoptotic TUNEL+ cells in NSG mice to generate orthotopic xenografts, confirming that Quisinostat treatment induced cytostasis, not cell death, in vivo.
Quisinostat dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2020 Apr 14;11(1):1792. [Abstract]
Quisinostat (4 mg/kg; i.p.; once daily) strongly inhibited tumor maintenance in the three PDX models of lung, pancreas and breast cancer.
Quisinostat dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2020 Apr 14;11(1):1792. [Abstract]
Quisinostat (100 nM; 24 h) decreased total and phosphorylated SMAD2 (p-SMAD2) in HCC1569 cells.
Quisinostat dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2020 Apr 14;11(1):1792. [Abstract]
Quisinostat (4 mg/kg; i.p.; 21 d) treatment increased the levels of E-cadherin of HCC1569-induced orthotopic xenografts in NSG mice, indicating a reversion to a more epithelial phenotype.
-
Exp Hematol Oncol
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma. [Abstract]2019 Nov 15:8:30. PMID: 31788346 -
Theranostics
Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy. [Abstract]2019 Jan 30;9(4):1096-1114. PMID: 30867818 -
Adv Sci (Weinh)
Macrophage TRIM21 Inhibition Ameliorates Murine Acute Pancreatitis via PHB2-Mediated Mitochondrial Stabilization. [Abstract]2026 Jan 22:e17877. PMID: 41572443 -
NPJ Precis Oncol
Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy. [Abstract]2023 Jul 21;7(1):70. PMID: 37479885 -
EMBO J
Acetylation of TIR domains in the TLR4-Mal-MyD88 complex regulates immune responses in sepsis. [Abstract]2024 Nov;43(21):4954-4983. PMID: 39294473 -
Blood Adv
2024 Sep 24;8(18):4936-4947. PMID: 38916861 -
Cancer Cell Int
Epigenetic potentiation of 5-fluorouracil by HDAC inhibitor quisinostat enhances antitumor effects in colorectal cancer. [Abstract]2025 Oct 8;25(1):340. PMID: 41063169 -
Antimicrob Agents Chemother
2025 Sep 3;69(9):e0181924. PMID: 40741955 -
Toxicol Appl Pharmacol
Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis. [Abstract]2021 Jan 1:410:115363. PMID: 33290780 -
-
-
-
-
-
Solvent & Solubility
DMSO : 31.25 mg/mL (66.86 mM; ultrasonic and warming and heat to 70°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Vamsi Krishna Kommalapati, et al. Inhibition of JNJ-26481585-mediated autophagy induces apoptosis via ROS activation and mitochondrial membrane potential disruption in neuroblastoma cells. Mol Cell Biochem. 2020 May;468(1-2):21-34. [Content Brief]
[2]. Arts J, et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009 Nov 15;15(22):6841-51. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1395 mL | 10.6977 mL | 21.3954 mL | 53.4885 mL |
| 5 mM | 0.4279 mL | 2.1395 mL | 4.2791 mL | 10.6977 mL | |
| 10 mM | 0.2140 mL | 1.0698 mL | 2.1395 mL | 5.3489 mL | |
| 15 mM | 0.1426 mL | 0.7132 mL | 1.4264 mL | 3.5659 mL | |
| 20 mM | 0.1070 mL | 0.5349 mL | 1.0698 mL | 2.6744 mL | |
| 25 mM | 0.0856 mL | 0.4279 mL | 0.8558 mL | 2.1395 mL | |
| 30 mM | 0.0713 mL | 0.3566 mL | 0.7132 mL | 1.7830 mL | |
| 40 mM | 0.0535 mL | 0.2674 mL | 0.5349 mL | 1.3372 mL | |
| 50 mM | 0.0428 mL | 0.2140 mL | 0.4279 mL | 1.0698 mL | |
| 60 mM | 0.0357 mL | 0.1783 mL | 0.3566 mL | 0.8915 mL |
Quisinostat dihydrochloride Related Classifications
HY-15433A Related Classifications
Powered by Bioz